You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 李氏大藥廠(0950.HK)漲超5% 預期中期淨利同比增約20倍
格隆匯 08-16 09:48
格隆匯8月16日丨李氏大藥廠(0950.HK)現報4.28港元,漲5.42%,最新市值25億港元。李氏大藥廠上週五(13日)晚間發公吿稱,預計截至2021年6月30日止6個月的股東應占未經審核純利將較截至2020年6月30日止6個月增加約20倍。純利增加主要由於:(i)收益增加約4.9%;(ii)緊隨2021年4月29日兆科眼科上市後,終止將於兆科眼科的投資確認為本公司的聯營公司,產生一次性收益約23億港元;(iii)缺少去年同期所錄得因提前終止《再寧平》的產品特許授權而產生的一次性補償收入4120萬港元;(iv)藥物開發管道於2021年上半年快速推進,確認為費用的研發成本較去年同期增加約3770萬港元等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account